Dr Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger

Dr Ashleys Limited and Impact BioMedical Inc. (NYSE: IBO) have announced a strategic merger agreement on June 21, 2025. The transaction involves a reverse merger where Dr Ashleys will acquire Impact BioMedical, creating a new combined entity to be traded on NYSE American as Dr Ashleys Limited. The merger aims to leverage Dr Ashleys' global reach and financial capabilities to accelerate the market development of Impact BioMedical's patent portfolio. The combined company will be managed by Dr Ashleys' team with a new Board of Directors. The transaction has received unanimous approval from both companies' boards and is subject to shareholder approval, regulatory clearances, and SEC registration requirements. BMI Capital LLC and Revere Securities LLC are serving as M&A advisors to Dr Ashleys and Impact BioMedical, respectively.

https://www.stocktitan.net/news/IBO/dr-ashleys-limited-and-impact-bio-medical-inc-announce-strategic-zpdgpzvpkv0m.html